平台数智化上，药九九APP融合先进的智能推荐算法与区块链加密技术，实现了药品精准匹配与交易数 据安全存证，其Android版已获软件著作权；平台功能迭代升级智能搜索、智能客服系统、智能采购系 统与自动化核单等，大幅提升营运效率与履单效率。此外，平台拥有PC、App、小程序多个移动终端， 让上下游客户享有安全、高效、便捷、精准的服务体验。 2025年4月，药九九平台通过"湖北精品"标准先进性评价，药九九品牌在国内医药流通数智化领域影响 力显著提升。 九州通（600998）2025半年度业绩说明会9月3日上午举行，公司高管在与投资者进行深入交流时介绍了 药九九B2B电商平台业务的发展情况，其表示，公司以终端纯销模式为核心，全力发展院外医药数字化 平台业务，持续为诊所、中小连锁、药店等客户提供"一站式"采购、专业地推、供应链金融、SaaS系统 等服务。上半年，药九九B2B电商平台自营销售收入达63.04亿元，同比增长14.62%，业务规模实现较 大增长，成为医药行业领先的线上线下（300959）一体化数智化交易与服务平台。 此外，公司已建立起全国领先的"批零仓配一体化"医药物流供应链服务体系，通过29个药九九专仓( ...

Group 1 - The Hong Kong pharmaceutical sector has seen significant growth, with the Hong Kong pharmaceutical ETF rising over 2%, and companies like 3SBio, BeiGene, and Innovent Biologics showing strong performance, attracting investor attention [1] - The domestic largest out-of-hospital pharmaceutical sales platform, Yaoshi Bang, has experienced a strong upward trend in its stock price, with a year-to-date increase of over 68%, and a total market capitalization exceeding HKD 5.6 billion [1] - Yaoshi Bang reported its first annual profit in 2024, with a net profit of HKD 157 million, a year-on-year increase of 20.1%, and significant growth in high-margin business segments [1] Group 2 - The company has shown strong cash flow performance, with operating cash flow increasing from HKD 98.2 million in 2022 to HKD 656 million in 2024 [1] - A share buyback plan of HKD 100 million was announced, with a total of 4.457 million shares repurchased for over HKD 33.99 million from May 7 to May 21 [1] - The largest shareholder and founder of Yaoshi Bang has not sold any shares since the company went public in 2023, indicating stable ownership structure [2] Group 3 - Company executives have actively increased their holdings, with the executive director purchasing 700,000 shares between April and May, reflecting confidence in the company's future [2] - The digital pharmaceutical market in which Yaoshi Bang operates has significant growth potential, with increasing digital healthcare penetration and demand from grassroots levels [2] - Despite a slight pullback, the company's stock price has maintained an upward trend for two consecutive weeks, supported by strong fundamentals and the share buyback plan [2]

Company Background and Transformation Drivers - Jiangxi Yintao Pharmaceutical Co., Ltd. is a national high-tech enterprise engaged in R&D, production, and sales, covering traditional Chinese medicine, chemical raw materials, and formulations, with products spanning 9 categories, 18 series, and 158 drug approvals [1] - The company faces challenges due to new medical reforms, centralized procurement policies, intensified market competition, and stricter regulations, including a lack of unified information platforms, compliance issues, and disorganized accounts receivable [2] Solution Design and Platform Deployment - Yintao Pharmaceutical has chosen to deploy Kingdee Cloud's flagship version to create an integrated platform of "ERP + GSP Compliance Cloud," aiming for unified master data standards and seamless business chain connectivity [3] Key Construction Highlights - A centralized ERP platform has been established to manage master data and close business process loops, enhancing collaboration across subsidiaries [5] - Integration of GSP compliance processes with the ERP supply chain ensures drug quality traceability and operational efficiency [6] - A dual-dimensional credit and receivables management system has been implemented to mitigate bad debt risks [7][8] - A unified financial accounting system has been created to enable detailed cost accounting and business-financial integration [9] Impact of Digital Transformation and Management Value - The establishment of a complete digital marketing chain allows real-time order status tracking and profit visibility for sales personnel and managers [10] - Enhanced inventory visibility and customer satisfaction through real-time data across procurement, production, quality, and sales [11] - The multi-organization accounting structure supports both corporate financial accounting and internal management, driving cost reduction and profit enhancement [12] Summary - Jiangxi Yintao Pharmaceutical, in collaboration with Kingdee Cloud, is transforming its operations with a focus on "full-process business closure + GSP compliance control + financial standard enhancement," moving from fragmented systems to a unified platform and from coarse management to refined operations, thereby strengthening its resilience and preparing for high-quality growth in the capital market [13]